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Development and validation for research assessment of
Oncotype DX® Breast Recurrence Score, EndoPredict® and
Prosigna®
Richard Buus 1,2, Zsolt Szijgyarto3, Eugene F. Schuster1,2, Hui Xiao1,2, Ben P. Haynes2, Ivana Sestak 4, Jack Cuzick4, Laia Paré5,6,
Elia Seguí5,6, Nuria Chic5,6, Aleix Prat 5,6, Mitch Dowsett 1,2 and Maggie Chon U. Cheang3✉
Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of
Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with oestrogen-receptor-positive (ER+),
HER2-negative breast cancer. Here, we describe the development and validation of methods to recapitulate RS, EP and ROR scores
from NanoString expression data. RNA was available from 107 tumours from postmenopausal women with early-stage, ER+, HER2−
breast cancer from the translational Arimidex, Tamoxifen, Alone or in Combination study (TransATAC) where previously these
signatures had been assessed with commercial methodology. Gene expression was measured using NanoString nCounter. For RS
and EP, conversion factors to adjust for cross-platform variation were estimated using linear regression. For ROR, the steps to
perform subgroup-specific normalisation of the gene expression data and calibration factors to calculate the 46-gene ROR score
were assessed and verified. Training with bootstrapping (n= 59) was followed by validation (n= 48) using adjusted, research use
only (RUO) NanoString-based algorithms. In the validation set, there was excellent concordance between the RUO scores and their
commercial counterparts (rc(RS)= 0.96, 95% CI 0.93–0.97 with level of agreement (LoA) of −7.69 to 8.12; rc(EP)= 0.97, 95% CI
0.96–0.98 with LoA of −0.64 to 1.26 and rc(ROR)= 0.97 (95% CI 0.94–0.98) with LoA of −8.65 to 10.54). There was also a strong
agreement in risk stratification: (RS: κ= 0.86, p < 0.0001; EP: κ= 0.87, p < 0.0001; ROR: κ= 0.92, p < 0.001). In conclusion, the
calibrated algorithms recapitulate the commercial RS and EP scores on individual biopsies and ROR scores on samples based on
subgroup-centreing method using NanoString expression data.
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INTRODUCTION
Over 80% of breast cancer patients in the developed western
world have oestrogen receptor (ER)-positive disease1,2; their
treatment normally includes surgery and adjuvant endocrine
therapy (ET), and sometimes chemotherapy (CT) which greatly
improves outcome3. However, a substantial risk remains for
relapse.
Multi-parameter gene-expression-based prognostic signatures
are often used to estimate the residual risk of recurrence after
surgery to guide patient management. Amongst the most widely
used prognostic signatures in ER+ breast cancer are the Oncotype
DX Recurrence Score (RS)4, EndoPredict (EP/EPclin)5 and Prosigna®
Risk Of Recurrence score (ROR)6. Each of these have been
endorsed for prognostic use in authoritative guidelines 7,8.
RS consists of 16 prognostic genes and five reference genes
assessed by RT-PCR. Thirteen of the prognostic genes are grouped
into four modules (proliferation, oestrogen, HER2 and invasion),
which allow these features to be weighted differently in the
signature algorithm with scale between 0 and 1004. The HER2 and
proliferation modules are thresholded such that quantitative read-
outs from those modules are only differentiated in tumours with
high expression for the respective modules. The 16 genes were
selected from 250 candidates on tumours collected from a mixed
cohort of 447 patients collected including the tamoxifen arm of
NSABP B-20 trial. The cut-points for individual gene expression
were based on the results from NSABP B-20 trial4. The final RS
algorithm was validated on 668 tamoxifen-treated patients from
the NSABP B-14 trial, an ER+, node-negative cohort that contained
both HER2-positive and -negative patients. RS does not include
clinico-pathological information beyond the molecular score. An
RS-pathology-clinical model was developed that improves the
prognostic performance of RS9, but this seems to be used
infrequently in clinical practice. Cut-off points for RS were
established to classify patients into low (RS < 18), intermediate
(18 ≤ RS ≤ 31) and high risk (RS > 31). The RS has been validated in
NSABP B-2010, TransATAC11 and SWOG 881412. More recently the
TAILORx study reported findings for the reduced cut-points of 11
and 26, respectively13, showing women with hormone receptor-
positive, HER2-negative, axillary node-negative breast cancer, and
a high RS of 26 to 100 had better prognosis when treated with ET
with adjuvant CT regimens than expected with ET alone; however,
there was a lack of CT benefit in patients with RS < 2613,14.
The molecular EP score consists of eight prognostic and four
reference genes measured by RT-PCR, and ranges between 0 and
15 with a cut-off value of 5 categorising patients into low- and
high-risk groups5. The clinically applicable EPclin, combines the
molecular EP score with tumour size and nodal status where the
EPclin value of 3.3 splits patients into low- or high-risk categories5.
EP and EPclin were trained in an ER+/HER2− population that
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included patients with both node-negative and -positive disease
(n= 664). EP and EPclin were validated in ABCSG-6 and -8 trials5
and in TransATAC15.
Breast cancers can be classified into one of five intrinsic
subtypes, namely Luminal A, Luminal B, Basal-like, HER2-enriched
and Normal-like by gene expression profiling16. The PAM50
algorithm is based on measurement of 50 genes optimally
selected to classify the five intrinsic subtypes and eight reference
genes6. The clinically applied Prosigna® score uses 46 of the 50
intrinsic subtype genes, as measured by the NanoString nCounter,
integrated with a proliferation score and tumour size information
based on the ROR-PT formula17,18 and referred as ROR score here.
The ROR score was validated in TransATAC19, ABCSG-817 and
DBCG cohorts20 to predict risk of relapse for postmenopausal
women with hormone receptor-positive, node-negative (Stage I or
II) or node-positive (Stage II or IIIA) early-stage breast cancer to be
treated with adjuvant ET. The final ROR score ranges from 0 to 100
and the risk is calculated differently depending on the nodal
status; specifically, node-negative cancers are classified as low
(0–40), intermediate (41–60) or high (61–100) risk, 1–3 node-
positive cancers are classified as low (0–15), intermediate (16–40)
or high (41–100) risk and 4+ node-positive cancers are classed as
high risk. The PAM50 genes are measured by the NanoString
nCounter which allows the detection of up to 800 RNA species in
extracts from formalin-fixed tissues by utilising molecular ‘bar-
codes’, direct hybridisation, and single molecule imaging without
amplification steps that might introduce bias21. NanoString is
widely used for clinical and biomarker research studies of gene
expression in FFPE22.
Here, we describe the derivation and validation of RS and EP
and ROR scores within ER+/HER2− tumours using gene expres-
sion data simultaneously generated by the NanoString nCounter
System. We also provide a step-by-step protocol as reference and
a guide for computing these scores to allow other researchers to
assess the prognostic and predictive value of these scores in
research studies.
RESULTS
Computation and verification of conversion factors for RS and
EP in the training set
The gene-wise conversion factors for RS and EP derived from the
TransATAC training cohort (n= 59) are listed in Tables 1 and 2,
respectively. When applied in the training set (n= 59) there were
linear relationships between the RS gene expression levels
measured by RT-PCR and NanoString for all genes with the
exception of CTSL2 and GSTM1 due to the lack of expression
detected in some samples by the NanoString assay (Supplemen-
tary Fig. 1). All the EP genes had linear association between the
expression levels measured by RT-PCR and NanoString TransATAC
training cohort (n= 59) (Supplementary Fig. 2).
Verification of conversion factors and adjusted expression
levels for RS and EP in the validation set
An independent cohort of TransATAC (n= 48) was used for the
validation of the gene-wise conversion factors. The averaged
correction coefficients (Tables 1 and 2) were imputed to adjust
the NanoString-derived gene expression levels. Overall, the fit of
the adjusted gene expression levels on the commercial gene
expression levels for RS and EP was good (Supplementary Figs. 3
and 4). Concordance correlation coefficients (ccc) were >0.85 for
all individual RS genes except for MYBLE2, AURKA, CTSL2 and
GSTM1 (Supplementary Table 1). Following the adjustment, the
expression level of MYBL2 was overestimated at lower values and
underestimated at higher values. Values that were previously
undetected by NanoString were shifted from a value of 0 to higher
adjusted log2 values, which was noticeable for CTSL2 and GSTM1.
For EP, there was a good concordance between the two assays for
all EP genes (ccc ≥ 0.84; Supplementary Table 2).
Evaluation of the RUO RS and EP scores in the validation set
The RS module scores were computed using the algorithms
described by Paik et al.4. The commercial and adjusted, research
use only (RUO) NanoString RS module scores were highly
correlated; (ccc) rc was 0.91 0.93, 0.98, 0.88, 0.91 and 0.95 for
the proliferation, thresholded proliferation, oestrogen, invasion,
HER2 and thresholded HER2 modules, respectively (all p < 0.0001;
Supplementary Fig. 5). There was disparity for four samples in the
module thresholdings between the commercial and RUO
methods.
Table 1. Averaged conversion factors for each gene expression level



























Table 2. Averaged conversion factors for each gene expression level














R. Buus et al.
2













The ccc for the commercial and RUO RS and EP risk scores were
close to one: rc(RS)= 0.96 (95% CI 0.93–0.97) and rc(EP)= 0.97
(95% CI 0.96–0.98) (Fig. 1). The high level of agreement between
the commercial and RUO RS risk scores was also supported by
Bland-Altman plots (Supplementary Fig. 6a, b). For RS, the mean
difference between the commercial and RUO RS was Δ(average
RS)= 0.21, 95% LoA −7.69 to 8.12. For EP, the mean difference
between the commercial and RUO EP scores was Δ(average EP)=
0.31, 95% LoA −0.64 to 1.26.
The validation set samples were classified into risk groups
according to the pre-specified cut-points for the RS4 and EP5
scores. For RS, comparing the commercial and RUO risk groups, of
the 48 validation samples, there were 6 (12.5%) cases misclassified
by the RUO RS when compared with the commercial RS
classification results (Fig. 1a and Table 3). The kappa statistic
measuring the agreement between the risk groups defined by the
commercial and RUO RS was κ= 0.86 (95% CI 0.74–0.97); p <
0.0001. Since the report of TAILORx trial results, the cut-offs for RS
to identify patients who may benefit to additional CT are 26 for
postmenopausal women and 16 for premenopausal, we had
repeated our comparisons based on these cut-offs (Supplemen-
tary Table 3). The agreements between the commercial and RUO
risk groups were substantial with κ= 1.00 (95% CI 1.00–1.00) for
cut-off at 26 and κ= 0.83 (95% CI 0.68–0.99) for cut-off at 16,
respectively.
For EP, there were three patients (3/48, 6.3%) at low risk
according to the commercial EP score who were categorised into
the high-risk group by the RUO EP (Fig. 1b and Table 4). The kappa
statistic measuring the agreement between the commercial and
RUO EP risk groups was κ= 0.87 (95% CI 0.73–1.00, p < 0.0001).
The equivalent of the clinically applicable EPclin may be calculated
using the EPclin algorithm5.
Computation and verification of the RUO ROR
The scaling of the TransATAC dataset to a 229 patient ER+/HER2−
cohort assayed previously with the Prosigna® test enabled the
robust calculation of subtypes and RUO ROR scores. There was
good correlation between the RUO ROR score with the
commercial Prosigna® ROR score in the training set (n= 59), with
ccc rc(ROR)= 0.95 (95% CI 0.92–0.96) (Supplementary Fig. 7).
Fitting a linear regression analysis on these 59 cases, we
computed the RUO factors contributing to the formula as set
out in Eq. (1):
RUO ROR ¼ 12:8536578þ 0:7688329 ´ unadjusted RORð Þ (1)
The commercial ROR and RUO ROR scores were highly
correlated in the validation set (n= 48) with the ccc rc(ROR)=
0.97 (95% CI 0.94–0.98) (Fig. 2a). The discrepancies between the
measurements was visualised using the Bland-Altman plot
(Supplementary Fig. 6c) and the bias was low at 0.43 with LoA




























Fig. 1 Assessment of relationship between commercial and RUO
versions of RS and EP scores. Assessment of correlation (A)
between commercial RS and RUO RS as well as (B) between
commercial EP scores and RUO EP scores using the validation set
(n= 48). Patients are represented in low-risk group with green, in
intermediate-risk group with orange and in high-risk group with red
as categorised by the commercial tests. RS: Recurrence Score; EP:
EndoPredict; NS: NanoString; RUO: research use only.
Table 3. Classification of 48 validation set patients into risk groups
based on the commercial and RUO RS.
Commercial RS (RT-PCR) RUO RS (NanoString-derived)
Low Intermediate High Total
Low 24 3 0 27
Intermediate 2 7 1 10
High 0 0 11 11
Total 26 10 12 48
Table 4. Classification of 48 validation set patients into risk groups
based on the commercial and RUO EP scores.





Low 17 3 20
High 0 28 28
Total 17 31 48
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Samples were classified into risk groups as set out for the
Prosigna®. The kappa statistic measuring the agreement between
the commercial and RUO ROR risk groups was κ= 0.92 (95% CI
0.84–1.00; p < 0.001) in the validation set (Table 5). Nodal status
was not available for one patient of the validation set, however,
despite this, risk classification was possible due to high
commercial and RUO ROR values (>70) both classifying this
patient as high risk. There were 3 cases classified differently (6.3%)
between these two methods: one node-negative patient was
classified as high risk by RUO (RUO ROR= 61.6; luminal B subtype)
and intermediate risk by the commercial ROR (ROR= 51.6; luminal
B subtype); the second sample was low risk by the RUO (RUO ROR
= 35.2; luminal A subtype) and intermediate by the commercial
ROR (ROR= 42.3; luminal A subtype); the third sample was
intermediate risk by ROR (RUO ROR= 48.1; luminal B subtype) and
low risk by the commercial ROR (ROR= 39.4; luminal A subtype).
Subtype classifications
Of the 59 TransATAC cases within the training set, there were 19
(32.2%) cases defined as Luminal B, 26 (44.1%) as Luminal A, 8
(13.6%) as HER2-enriched and 6 (10.2%) as Normal-like subtypes.
Of the 48 TransATAC cases within the validation set, there were 15
(31.3%) cases defined as Luminal B, 14 (29.2%) as Luminal A, 9
(18.8%) as HER2-Enriched, 3 (6.3%) as Basal-like and 7 (14.6%) as
Normal-like subtypes. The intrinsic subtype assignments by
commercial Prosigna® and RUO ROR were compared for all
TransATAC samples (n= 107). The Prosigna® test does not use
Normal-like subtype for subtype assignment. When a sample is
classified as Normal-like subtype, the subtype with the second
highest correlation coefficient (usually Luminal A) is used for
assignment. Supplementary Table 4 shows the contingency table
of subtype calls by the RUO NanoString and Prosigna® methods
on the 107 cases, combining the training and validation set,
disregarding the Normal-like subtype (i.e. using the second
highest correlating subtype if classified Normal-like) with 9 of 58
Prosigna® Luminal A and 14 of 43 Luminal B subtypes classified as
other subtypes by the RUO method.
Estimation on the variability of the RUO ROR algorithms on
external gene expression data
A dataset of 146 patients with ER+/HER2− disease from the
Hospital Clinic of Barcelona previously tested with Prosigna® and
analysed with three different NanoString panels of genes were
used for an independent evaluation of the RUO ROR algorithm. In
the first cohort of 10 samples, the gene expression data was
generated using a custom panel of 110 genes and tumour size
information was available for 7 of these samples. The commercial
ROR and our RUO ROR scores were highly correlated with ccc rc=
0.85 (95% CI 0.57–0.96) (Supplementary Fig. 8a). In the second
cohort of 29 samples, the commercial ROR and our RUO ROR
scores were correlated with ccc rc= 0.60 (95% CI 0.38–0.75)
(Supplementary Fig. 8b). In the third cohort of 107 samples, the
commercial ROR and our RUO ROR scores were correlated with
ccc rc= 0.66 (95% CI 0.57–0.74) (Supplementary Fig. 8c). We
combined these three cohorts to determine the agreement of risk
groups assigned by these two methods. While there was a good
agreement between the ROR scores (rc= 0.79 (95% CI 0.74–0.84))
within this cohort of mainly high-risk samples (Fig. 2b), the
agreement of categorised risk groups was only fair with a kappa
statistics of 0.65 (95% CI –0.45 to 0.86) (Table 6), having 4 cases































Fig. 2 Figure Assessment of relationship between Prosigna® and
RUO ROR scores. Comparison of commercial Prosigna® scores and
RUO ROR scores (A) within the TransATAC validation set (n= 48) and
(B) within the combined Spanish cohort (n= 143). Patients are
represented in low-risk group with green, in intermediate-risk group
with orange and high-risk group with red as stratified by the
commercial test. RUO: research use only.
Table 5. Classification of 48 validation set patients into risk groups
based on the commercial and RUO ROR scores.




Low 8 1 0 9
Intermediate 1 12 1 14
High 0 0 25 25
Total 9 13 26 48
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DISCUSSION
Multi-parameter prognostic signatures are widely used for the
prognostication and treatment guidance of ER+/HER2− primary
breast cancer patients. We have developed and validated RUO
algorithms based on NanoString expression data that closely
approximates the commercial prognostic RS, EP and ROR assay
scores that are endorsed by international guidelines. In addition,
we provided detailed guidelines on how to use the algorithms
with the ultimate aim that these can be used for academic clinical
research studies, and also how to apply the analytical approach
should one wish to compute their own calibration factors
internally. A subset of the TransATAC set of samples was selected
for this study where the respective prognostic scores had
previously been measured by each assays’ commercial developers.
Based on the prognostic information available, the cohort was
selected to encompass a wide range of recurrence risks.
RS is a purely molecular score without clinical component where
we decided to adjust the individual genes. EP, a component of
EPclin, is also a molecular score for which the adjustment factors
were calculated for individual genes in a similar fashion. For ROR,
partly due to the same assay platform being used for the
commercial and RUO versions we did not adjust individual genes;
instead adjustment to the clinically applicable ROR-PT score was
used, an algorithm that also includes a proliferation score and
tumour size.
For the RS signature CTSL2 and GSTM1 were not detected in all
samples by NanoString. Despite the difficulty in correlating these
genes at the lower range of expression, the correlation of individual
RS modules and the final score were strong between the
commercial RT-PCR-based and RUO NanoString-based data in the
validation set, demonstrating the robustness of the RUO RS. For EP
there were no gene detection issues and the commercial RT-PCR-
based and RUO NanoString-based scores showed a near-perfect
agreement in the validation set. For ROR we found good correlation
between the final ROR scores obtained by the commercial and RUO
methods. There was also good agreement in patient stratification
between the commercial and RUO NanoString-based data for all
three signatures; this attests that the applied methods adjust well
the risk scores obtained by NanoString capturing the information
embedded in the commercial risk scores.
There is great interest in computing accurate RS, EP and ROR
scores for academic clinical research. Attempts have been made to
recapitulate these and other commercial prognostic scores using
expression data derived by gene expression microarray23–25, RT-
PCR26,27, RNA-sequencing25 and NanoString28. However, the
surrogate scores are rarely compared to their commercial
counterparts derived from the same samples. The main reason
is the high cost of the commercial tests which is a substantial
impediment in academic studies. The availability of validated
signatures at an economically viable cost could facilitate further
studies to understand the clinical behaviour of these prognostic
gene signatures, predict treatment response and late recurrence,
and better understand the impact of different clinical settings on
their expression (e.g. the impact of HRT, medical therapies before
surgery and phases of the menstrual cycle). Additionally, it would
allow the head to head comparative analysis of newly discovered
genomic signatures with these three clinically well-established
molecular signatures. However, we stress that the presented RUO
prognostic scores should not be used for patient management.
Our study has strengths and weaknesses. Strengths include that
the samples used in this study are from a well-characterised and
documented set of samples. RNA samples have been assayed by
the commercial tests’ developers using their commercial proprie-
tary methods used in the clinic. For each patient the same aliquot
of RNA was used for the measurements of the commercial assays
(RS, EP, ROR) and for the NanoString assay to calculate RUO scores.
This eliminated issues related to intratumour heterogeneity and
allowed us to calculate more accurate RUO scores. For ROR
calculations we used a 229 patient ER+/HER2− scaling cohort
which enabled the robust derivation of RUO ROR scores relevant
for this TransATAC cohort. The accuracy of conversion factors was
confirmed by an independent validation set of 48 samples.
Weaknesses include that the RUO adjustment parameters are
optimised for NanoString-based assay, and if working with
expression data obtained on different platforms (e.g. RT-PCR,
microarray), the normalisation and adjustment factors described
here are not applicable. The commercial Prosigna® subtype
correlation data and confidence of subtype calls are not available
for this TransATAC dataset and it is therefore not possible to
accurately determine the robustness of the RUO subtype
classification, as samples may have a high confidence correlation
with more than one subtype. Meanwhile, our development work
had eliminated issues related to intratumour heterogeneity, and
the possible variability generated by different RNA quality among
a central and a peripheral lab may have been underestimated. In
addition, it was a challenge to identify and gain access to external
datasets that had been subjected to commercial RS, EP and ROR
assays with residual RNA available to assess the accuracy of the
conversion factors on data generated by custom gene expression
panels in other laboratories. While we were able to assess the
variability of ROR scores calculated based on the RUO ROR
algorithm using external cohorts from Hospital Clinic of Barcelona,
this cohort was biased with much higher risk29 than a random
population of early ER+/HER2− breast cancer.
A RUO EP and RS can be calculated for individual biopsies;
however, for RUO ROR to be calculated for individual samples,
improvement is needed for better precision as demonstrated on a
testing set of 20 samples (ccc rc= 0.77 (95% CI 0.59–0.88);
Supplementary Fig. 9)). Calculation of RUO ROR scores requires
generating an ER+/HER2− dataset that roughly matches the cohort
of the 229 sample ER+/HER2− tumours used to scale the
normalised expression values for each gene. Significant differences
between a research dataset and this cohort (e.g. if research dataset
is highly enriched for high-risk subtypes) will mean RUO ROR scores
will be miscalculated. This weakness might be overcome by the
selection of a different cohort for scaling that better matches the
dataset of interest or by generating commercial Prosigna® scores
for a subset of the dataset that can be used to calculate custom
adjustment factors for final RUO scores.
In summary the results presented here show that the RUO
NanoString-derived versions of RS, EP and ROR scores closely
recapitulate the commercial assessments and may be used to
provide high level of discrimination between patients in distinct
risk groups as defined by the commercial assays.
METHODS
Patient samples and study design
The ATAC (anastrozole or tamoxifen alone or in combination) trial
evaluated efficacy and safety of anastrozole vs tamoxifen given for 5
years in postmenopausal women with localised primary breast cancer30.
Table 6. Classification of 143 external validation cohort patients into
risk groups based on the commercial and RUO ROR scores.




Low 2 4 0 6
Intermediate 0 10 17 27
High 0 1 109 110
Total 2 15 126 143
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TransATAC is a collection of patients randomised to the monotherapy arms
of the ATAC trial from which 107 ER+/HER2− patients were selected for
the current study with the aim to represent low-, intermediate- and high-
risk patients where the risk assessments were based on the commercial
prognostic tests available in these patients.
Our analytical approach is to compute conversion factors by modelling
the gene expression data values measured by NanoString with those
assessed by the commercial assays (Supplementary Fig. 10). Stratified by the
risk groups, tumour size and nodal status, we randomly split the 107 cases
into training set (n= 59) for development and validation set (n= 48) to
determine the correlation coefficient between the RUO and their
commercial scores. In order to detect a positive relationship (i.e. correlation
>0.4) with 85% power and 0.05 significance level, we would need at least 42
cases. Furthermore, as a secondary analysis, 48 cases would also have
approximately 86% power to detect 20% variability of the model at a
0.05 significance level. The Hospital Clinic of Barcelona cohorts are three sets
of patient samples with ER+/HER− disease previously tested with Prosigna®.
This study was approved by the South-East London Research Ethics
Committee and all patients provided written informed consent for their
tissue to be used in translational research.
RNA for the TransATAC samples was extracted by Genomic Health Inc.
(GHI)11. For this study, eligibility required hormone receptor-positive, HER2-
negative disease where commercial RS, ROR and EP analyses had been
performed by the manufacturer according to the manufacturer protocol
using the commercially available test and sufficient amount of residual RNA
was available. Measurements of the commercial RS11, EP15 and ROR19 in
TransATAC have been described previously11,15,19. For each tumour,
150–200 ng RNA was used to measure expression of signature genes
constituting the RS, EP and ROR on the nCounter® FLEX Analysis System
using a custom gene expression panel of 82 genes. In the current study 72
genes were analysed including 12 reference genes (Supplementary Table 5).
For the Hospital Clinic of Barcelona cohorts, a minimum of ∼125 ng of total
RNA from formalin-fixed paraffin-embedded tumours (FFPE) were run with
one of three different panels: a custom 110 genes panel (n= 10), a custom 60
genes panel (n= 29) and the NanoString Breast Cancer 360™ panel (n= 107).
Data normalisation procedures
Data normalisation was performed using R version 3.6.3. Raw
NanoString output data was normalised using the NanoStringNorm
R package31.
Normalisation procedure of training set for RUO RS and EP
For the training set (n= 59), the RS and EP signature genes were







The commands performed the following: (1) Normalisation of raw data
with the geometric mean of the positive controls; (2) Background
correction by subtracting the mean of the negative probes; (3) Normal-
isation with the geometric mean of the housekeeping genes of the
respective signature; (4) Setting of <1 values to 1; and (5) Log2
transformation of normalised data.
Additionally, from this set of 59 samples we calculated the average of
geometric means of the positive controls before normalisation across the
samples (TransATAC-pos) and the average of TransATAC housekeeping
geometric means across the samples (TransATAC-hkgm). These parameters
were used for the normalisation procedure of the validation set.
Normalisation procedure of validation set for RUO RS and EP
For the independent validation set of 48 TransATAC samples the RS and EP










These commands performed the following: (1) Normalisation of raw data
with the geometric mean of the positive controls setting the target to
TransATAC-pos; (2) Background correction by subtracting the mean of the
negative probes; (3) Normalisation with the geometric mean of the
housekeeping genes of the respective signature setting the target to
TransATAC-hkgm; (4) Setting of <1 values to 1; and (5) Log2 transformation
of normalised data. *TransATAC-hkgm was 5627.777; the TransATAC-pos
for RS was 2461.699 and for EP 8621.201. To utilise the conversion factors
described in this study we recommend applying the same normalisation
parameters as used for the validation set.
Normalisation procedure for RUO ROR in the training and
validation sets
Raw data was normalised with the following parameters; expression
counts plus 1 were log2 transformed and then the geometric mean of the
log2 transformed eight housekeeping genes (ACTB, GUS, MRPL19, PSMC4,
PUM1, RPLP0, SF3A1 and TFRC) were subtracted from all log2-transformed
expression values.
Estimation of calibration factors — cohort of samples based
Subgroup-specific gene centreing was performed. In brief, the normalised
expression data was scaled to a cohort of 229 sample ER+/HER2− tumours
previously subjected to the Prosigna® assay (named ERPosHER2Neg)
(Supplementary Data 1). Under the assumption that this ER+/HER2−
cohort and the TransATAC cohort were similar, gene-wise differences in
the median of these two groups represent possible technical and sample
bias. To remove such differences, the TransATAC cases were normalised to
the ERPosHER2Neg cases. The normalisation factor for each gene was
calculated (Supplementary Table 6), and could be applied for other studies
of ER-positive tumours. The same calibration factor was applied in the
validation cohort (n= 48) in this study. The publicly available intrinsic
subtype centroids were derived from microarray data, we had scaled our
NanoString dataset to a technical calibration factor (Supplementary Table
7) prior to the intrinsic subtype classification6.
Applying the RUO ROR algorithm on Spanish cohorts
The same procedure, as described above, was applied on three set of
patients collected externally to assess the agreement of RUO ROR score
computed based on our coefficients on different custom NanoString
gene panels in other laboratories. The RUO ROR algorithm was applied in
each cohort separately as follows. For each cohort, raw data of the 46
ROR genes and 8 housekeeping genes were processed and normalised
following the RUO ROR normalisation procedure as described above.
Subgroup-specific centreing was performed on the normalised expres-
sion data by subtracting the TransATAC-to-ERPosHER2Neg normalisation
factor (Supplementary Table 6) for each gene. Intrinsic subtypes were
called by applying the PAM50 classifier with the technical calibration
factor for NanoString dataset (Supplementary Table 7)6. Following the
PAM50 subtyping, the ROR score was calculated based on the ROR-PT
formula17,18. The RUO ROR score was obtained by adjusting the ROR
score with the RUO factors.
Data analysis
Development of NanoString RUO RS and EP algorithm. Our analysis
pipeline consisted of two steps: (1) estimation of conversion factors in the
training set (n= 59) and (2) validation of the conversion factors on an
independent validation set (n= 48) (Supplementary Fig. 10).
Estimation of conversion factors in the training set (n= 59).
● Computation of conversion factors were repeated 30 times (Iteration,
I= 30) using a cross-validation approach. The TransATAC training
dataset of 59 samples was split into training (sample size, N= 39) and
test (sample size, N= 20) by random sampling (Iteration, I= 30). For
each iteration, gene-wise conversion factors (intercept and slope) were
obtained using linear regression models and were applied to adjust
NanoString data using Eq. (2):
adjusted geneNS;zi ¼ β0;zi þ βzi ´geneNS;zi
 
(2)
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where adjusted geneNS,zi is the adjusted NanoString mRNA level of
gene (i), β0,zi is the intercept of gene (i) and βzi is the linear coefficient
of gene (i) in iteration z= 1–30.
● The accuracy of conversion factors were evaluated by calculating the
% error between the adjusted NanoString gene expression levels and
the commercial RT-PCR gene expression level using Eq. (3):
Error %ð Þzi¼ median






where adjusted geneNS,zi is the adjusted NanoStringRNA level of gene
(i) for the 20 test set samples, geneRTPCR,zi is the RT-PCR mRNA level of
gene (i) in iteration z = 1–30 for the 20 test set samples.
For each gene the conversion factors (intercept and slope) giving











where β0,ci and βci are the average of β0,zi and βzi conversion factors giving
error of <10% for gene (i) in iteration z= 1–30, n is the number of the
coefficients averaged.
Validation of the conversion factors on an independent validation set
(n= 48).
● We applied the final conversion factors (β0,ci and βci of each gene) on
the independent validation set (n= 48) using Eq. (5):
Adjusted gene expression levels ¼ β0; ci þ βci x geneNSið Þ (5)
where β0,ci and βci are the average of conversion factors giving error of
accuracy < 10%.
● The RUO RS and EP scores were computed using the adjusted
NanoString data and the algorithms reported in the original RS and EP
publications5,10.
Development of NanoString RUO ROR algorithm
Following the normalisation and calibration described above, each tumour
was assigned to one of the four subtypes based on their similarities as
determined by Spearman correlation to the 46 gene-based expression
centroids as described by Parker et al.6,17. The centroids for the subtypes
are provided in Supplementary Table 8 for reference.
Following subtype assignment, the RUO ROR score was calculated
using Eq. (6)
ROR ¼ 54:7690 0:0067Basalþ 0:4317HER2E 0:3172LumAþ 0:4894LumBð
þ 0:1981Proliferation 18 geneð Þ þ 0:1133Tumour Size dichotomous on 2cmð Þ þ 0:8826Þ
(6)
where the proliferation score is the mean of 18 proliferation genes (ANLN,
CCNE1, CDC20, CDC6, CDCA1, CENPF, CEP55, EXO1, KIF2C, KNTC2, MELK,
MKI67, ORC6L, PTTG1, RRM2, TYMS, UCE2C and UBE2T) and tumour size is
the pathological tumour size (coded as 0 if ≤2 cm or 1 if >2 cm).
Using the 59 TransATAC cases, we also calculated adjustment factors
based on the linear regression Eq. (7):
RUO ROR½ ½  ¼ β0þ ðβ1 ´ unadjusted RORÞ (7)
which was used to adjust the final RUO ROR scores in the validation set.
Statistical tests
The correlation and agreement between the commercial and RUO
prognostic scores were measured by the concordance correlation
coefficient and Bland-Altman plot. The agreement between the risk
groups defined by the commercial and RUO risk scores was also evaluated
with the weighted kappa statistic. STATA and R were used for statistical
calculations. Normalisation of NanoString data and image generation were
performed with R version 3.6.1.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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